The miR Sentinel Prostate Cancer Test is a liquid biopsy urine test that uses molecular information to categorize patients into one of four groups: no cancer, low-risk cancer, intermediate-risk cancer, or high-risk cancer, thereby delivering clear, accurate and actionable results for physicians and their patients alike, answering key questions: Is cancer present? How severe is it?  
 
This information gives physicians the ability to clearly determine which patients need treatment and which can be safely and non-invasively monitored, helping avoid harmful and costly overtreatment.   
 
With data showing a sensitivity and specificity above 90%, there is a clear rationale for adoption of the miR Sentinel Prostate Test versus today’s standard of care, for the more than 1.2 billion men age-eligible for prostate cancer screening and detection around the globe. 

We anticipate that the miR Sentinel Prostate Test will be available in Puerto Rico and the United States (other than New York) by the end of 2021. The Test can only be ordered by your doctor, who will use the test as part of your care and treatment plan.   
 
Once the miR Sentinel Prostate Test is commercially available, we will update our website with information about costs, any patient assistance programs, and additional helpful details to share with your doctor when discussing your prostate cancer detection and treatment options. 
 
You may also subscribe to receive our communications via the Contact Us page on our website to receive notifications regarding news and updates of the miR Sentinel Prostate Cancer Test.  

Several clinical studies are now actively recruiting. Please visit the links provided below to the trial description on clinicaltrials.gov to review study information and eligibility.